RSA Viewpoints
Interim leaders are not ‘temps’ – choose wisely and reap the rewards
We’re all familiar with the concept – there’s an absence at work and we need some cover. A quick Google search and we send...
LEAP HR Life Sciences: HR with Impact and Agile Biotechs
Last week RSA attended LEAP HR: Life Sciences in Boston, Massachusetts. From past experience we were expecting a high value event and we were not disappointed....
Labelling of an Interim (or consultant; or freelancer)
I am often asked what defines an Executive Interim and the online community often seeks to debate this subject too. Veterans in the field...
What next for EU and UK biotech boards?
In light of the UK’s decision to leave the EU, it’s worth revisiting our recent Talent Equity® report on what makes successful biotech boards. The question...
Change in regulatory environment and the impact on talent
A view from the TOPRA Summit I approached the first TOPRA Summit in London at the end of May knowing that the world of healthcare...
Ipsen choose RSA Group as strategic partner for executive talent acquisition in Europe
We have been selected by Ipsen, one of the world’s leading innovators in patient care, as their chosen strategic partner in Europe for executive...
CRO talent: supplying scientific expertise
It’s hard to believe the speed of change in the preclinical CRO – pharma co. relationship over the recent years. Increasingly, preclinical contract research...
Consumer health – recruiting talent into a changing market
Fuelled by new technology and growing customer demand, consumer healthcare is burgeoning. Five-year forecasts predict growth of nearly 50% for the sector, up from...
Serving a changing market: agile approaches to modern problems
The life sciences industry is in a state of flux. An avalanche of change demands a radical response, redefining and (potentially) confusing the roles...
9th Annual European Life Science CEO Forum: the Impact on Talent: Advice to Clients
The ‘Davos’ of Life Sciences has been and gone for another year and the formal discussions focused on the evolving finance and M&A market,...
Future Talent Hard Data and Soft Skills
Imagine 1000 HR professionals in a theatre. Everyone with work and people challenges, mobile phones and email to answer. Cue Martine Wright, a survivor...
New thinkers needed – pharma supply chain management has entered a new world
Once seen as a less glamorous area of the pharma industry, supply chain management (SCM) is fast gaining a much higher profile. The talent...
Let’s face facts: it’s a candidate market for senior talent across life sciences
Tens of thousands of pharma jobs have been lost in recent years. So can smaller companies now select at leisure from an overflowing pool...
Biotech & Money, London, 2016
The meeting focused on harnessing the value of innovation and new models for collaboration. No small task. It had a strong UK focus but...
What Makes Successful Biotech Boards?
This report looks forensically at correlations between company performance and Board composition. From this we draw out lessons that can be learned from the...
New study looks at the impact of boards on biotech company performance
UK companies performing less well than those in mainland Europe RSA has published the latest of its Talent Equity® reports, an analysis of biotech company...
Report from JP Morgan 2016
The ‘Salmon Run’ of the Life Sciences is over for another year. Here are some take home messages. Public funding is uncertain but institutional investor coffers are full The withdrawal...
Talent equity is the long term value of biotech
Valuation of IP is familiar to every investor in the biotech sector and careful due diligence is essential before putting money at risk. We...